Overview

Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia

Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
To see if megestrol acetate plus rosuvastatin will be superior to reversing the endometrial lesion to a normal endometrium than megestrol acetate alone in patients with atypical endometrial hyperplasia (AEH). Considering the large sample size in RCT, we used Simon two-stage design.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Fudan University
Treatments:
Megestrol
Megestrol Acetate
Rosuvastatin Calcium